The FDA has approved the FGFR inhibitor erdafitinib for certain patients with urothelial carcinoma The U.S. Food and Drug Administration (FDA) has approved erdafitinib (Balversa) for the treatment of adult patients with locally advanced...
Enfortumab vedotin-ejfv plus pembrolizumab was approved for certain bladder cancers. The U.S. Food and Drug Administration (FDA) has approved enfortumab vedotin-ejfv (Padcev) plus pembrolizumab (Keytruda) for the treatment of patients with locally advanced or...
Antibody-drug conjugates link a targeted medication with a toxic drug to deliver a potent payload inside cancer cells.
A targeted therapy is now available for more patients with advanced bladder cancers The U.S. Food and Drug Administration (FDA) has granted accelerated approval to enfortumab vedotin-ejfv (Padcev) in combination with pembrolizumab (Keytruda) for...
The U.S. FDA approved an antibody-drug conjugate to treat urothelial cancer, the most common form of bladder cancer. The U.S. Food and Drug Administration (FDA) approved the molecularly targeted therapeutic enfortumab vedotin-ejfv (Padcev) to...
A new study reports that an inexpensive way to analyze DNA isolated from cells in urine is more sensitive than urine cytology, a microscopic examination of cells in the urine. When a doctor suspects...
Patients with bladder cancer who are treated with an immunotherapeutic may face worse outcomes if they also take proton pump inhibitors.
The FDA has approved an alternative dosing schedule for the immune checkpoint inhibitor pembrolizumab.
The FDA approved a molecularly targeted therapeutic for patients with advanced or metastatic urothelial cancer.
A study published in Cancer Prevention Research, a journal of the American Association for Cancer Research (AACR) reported that quitting cigarette smoking is associated with significantly reduced risk of bladder cancer. Bladder cancer is the fourth most common cancer in men and the ninth most common cancer in women.
AACR Fellow Lewis C. Cantley, PhD, leads a national effort targeting triple-negative breast cancer and ovarian cancer with a novel drug combination.
Learn MoreYour donation to the American Association for Cancer Research helps our more than 58,000 members worldwide drive progress against cancer.
Donate Now